12. Referencias bibliográficas

12. Referencias b ibliográficas

1 European Commission. EU Strategy. Disponible en: https ://ec.europa.eu/info/live-work-travel-eu/coronavirusres ponse/public-health_en [consultado el 21 febrero 2021]. 2 Mi ni sterio de Sanidad. Nota de prens a. El Mi nisterio de Sanidad s uspende a partir de mañana y durante l as dos próxi mas semanas l a vacunación con l a vacuna frente a l a COVID-19 de As traZeneca. Disponible en: https ://www.ms cbs.gob.es/gabinete/notasPrensa.do?id=5270 3 Mi ni sterio de Sanidad. Nota i nformati va. Suspensión cautel ar temporal de l a vacunación con As traZeneca.

Di s ponible en: https ://www.ms cbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/docs/Nota_AZ_

Sus pensionCautelar.pdf 4 Agenci a Es pañola de Medi camentos y Productos Sanitarios. Nota de Seguridad, 18 marzo 2021. Vacuna frente a l a COVID-19 de As traZeneca: conclusiones de l a evaluación del riesgo de tromboembolismo. Conclusiones del

Comi té para l a Evaluación de Ri esgos en Farmacovigilancia europeo (PRAC). Di sponible en: https ://www.aemps.gob.es/informa/notasinformativas/medicamentosusohumano-3/seguridad-1/2021s eguri dad-1/vacuna-frente-a-la-covid-19-de-astrazeneca-conclusiones-de-la-evaluacion-del-riesgo-detromboembolismo/ 5 Grupo de Trabajo Técnico de Vacunación COVID-19 de l a Ponencia de Programa y Regi stro de Vacunaciones.

Es trategi a de Vacunación frente a COVID-19 en Es paña. Consej o Interterritorial del SNS. Mi nisterio de Sanidad, 2 di ci embre 2020. Di sponible en: https ://www.ms cbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/docs/COVID19_Es trategi aVacunacion.pdf 6 Grupo de Trabajo Técnico de Vacunación COVID-19 de l a Ponencia de Programa y Regi stro de Vacunaciones.

Es trategi a deVacunación frente a COVID-19 en Es paña, Actualización 1. Consejo Interterritorial del SNS.

Mi ni sterio de Sanidad, 18 di ciembre 2020. Di sponible en: https ://www.ms cbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/docs/COVID19_Actualizacion1_Es trategiaVacunacion.pdf 7 Grupo de Trabajo Técnico de Vacunación COVID-19 de l a Ponencia de Programa y Regi stro de Vacunaciones.

Es trategi a de Vacunación frente a COVID-19 en Es paña, Actualización 2. Consejo Interterritorial del SNS.

Mi ni sterio de Sanidad, 21enero 2021. Di sponibleen: https ://www.ms cbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/docs/COVID19_Actualizacion2_Es trategiaVacunacion.pdf 8 Grupo de Trabajo Técnico de Vacunación COVID-19 de l a Ponencia de Programa y Regi stro de Vacunaciones.

Es trategi a de Vacunación frente a COVID-19 en Es paña, Actualización 3. Consejo Interterritorial del SNS.

Mi ni sterio de Sanidad, 9 febrero 2021. Di sponible en: https ://www.ms cbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/docs/COVID19_Actualizacion3_Es trategiaVacunacion.pdf 9 Grupo de Trabajo Técnico de Vacunación COVID-19 de l a Ponencia de Programa y Regi stro de Vacunaciones.

Es trategi a de Vacunación frente a COVID-19 en Es paña, Actualización 4. Consejo Interterritorial del SNS.

Mi ni sterio de Sanidad, 26febrero2021. Disponible en: https ://www.ms cbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/docs/COVID19_Actualizacion4_Es trategiaVacunacion.pdf 10 Fi cha técnica de COVID-19 Vaccine Janssen. CIMA, AEMPS. Di sponible en: https ://ci ma.aemps.es /cima/pdfs/es/ft/1201525001/FT_1201525001.pdf [consultado 26 marzo 2021] 11 Vas i leiou E, Si mpson CR, Robertson C, Shi T, Kerr S, et al . Effecti veness of Fi rst Dose of COVID-19 Vaccines

Agai nst Hos pital Admi ssions i n Scotland: Nati onal Prospective Cohort Study of 5.4 Million People. Available at

SSRN: https ://s srn.com/abstract=3789264 12 Lopez Bernal J, Andrews N, Gower C et al . Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on s ymptomatic disease, hospitalisations and mortality i n ol der adults i n England(Preprint 2 March 2021). Disponible en: https ://doi.org/10.1101/2021.03.01.21252652 13 Hyams C, Marlow R, Maseko Z et al . As sessing the Effectiveness of BNT162b2 and ChAdOx1nCoV-19 COVID-19

Vacci nation i n Prevention of Hospitalisations in El derly and Frail Adults: A Si ngle Centre Tes t Negati ve Case-

Control Study. The Lancet (Preprint 3 march 2021). Di sponible en: https ://papers.ssrn.com/sol3/papers.cfm?abstract_id=3796835 14 As traZeneca. Press rel ease, 22 March 2021. AZD1222 US Phase III tri al met pri mary effi cacy endpoint i n preventi ng COVID-19 at i nterim analysis. Disponible en: https ://www.astrazeneca.com/media-centre/pressrel eas es/2021/astrazeneca-us-vaccine-trial-met-primary-endpoint.html 15 As traZeneca. Press rel ease, 25 March 2021. AZD1222 US Phase III primary analysis confirms s afety and efficacy.

Di s ponible en: https ://www.astrazeneca.com/media-centre/press-releases/2021/azd1222-us-phase-iiipri mary-analysis-confirms-safety-andeffi cacy.html#:~:text=Positive%20high%2Dlevel%20results%20from,on%20Monday%2022%20March%202021. &text=The%20vaccine%20was%20well%20tolerated,to%20the%20vaccine%20were%20identified. 16 WHO. Interim recommendations for use of the AZD1222 (ChAdOx1-S (recombinant)) vaccine against COVID-19 devel oped by Oxford Uni versity and As traZeneca. Disponible en: https ://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1 17 Wi l liamson EJ, Walker AJ, Bhaskaran K, et al . Factors associated wi th COVID-19-related death using

OpenSAFELY. Nature 2020; 584:430–436. 18 Joi nt OTDT & BTS gui dance on SARSCoV-2 vaccination i n adult s olid organ and i slet transplantation wait-listed pati ents and adult l iving donor transplant recipients. https ://bts.org.uk/wpcontent/uploads/2021/01/DAT3911.pdf 19 Recomendaciones FACME s obre vacunación COVID-19 y trasplante de órganos. https://facme.es /wpcontent/uploads/2021/02/TC20210202-FACME-trasplante-organos-solidos-2801.pdf 20 Nai r V, Jandovitz N, Hi rsch JS, et al . A nearl y experience on the effect of s olid organ transplant s tatus on hos pitalized COVID-19 patients [e-pub ahead of print]. Am J Transplant . doi : 10.1111/ajt.16460 21 Col l E., Fernández-Ruiz M., Sánchez-Álvarez, J. E., et al . COVID-19 in transplant recipients: The Spanish experi ence. Am J Trans plant. doi.org/10.1111/ajt.16369, 2020 Oct 23 22 Wal eed M, Ars had MA, Abdallah M, Younossi ZM, Si ngal AK. Di sease s everity and ti me s ince transplantation determi ne pati ent mortality among l iver transplant recipients with COVID-19 i nfection: a meta-analysis [abs tract]. Hepatology 2020;72(1 Suppl):271A. http://dx.doi.org/10.1002/hep.31579 l u23 Sánchez-Álvarez JE, Pérez Fontán M, Ji ménez Martín C, Bl asco Pelícano M, Cabezas Rei na CJ, Sevi llano Prieto

ÁM, et al . SARS-CoV-2 infection in patients on renal replacement therapy. Report of the COVID-19 Registry of the Spanish Society of Nephrology (SEN). Nefrologia 2020; 40:272-8. https ://doi.org/10.1016/j.nefro.2020.04.002 24 Mal donado M, Os sorio M, Del Pes o G, Santos C, Ál varez L, Sánchez-Villanueva R, et al . COVID-19 incidence and outcomes i n a home di alysis unit i n Madrid (Spain) at the hei ght of the pandemic. Nefrologia 2020:S02116995(20)30166-1. (en prensa) https://doi.org/10.1016/j.nefro.2020.09.002. 25 Sol er MJ, Macia Heras M, Ortiz A, Del Pi no Y Pi no MD, Salgueira Lazo M. Impact of the COVID-19 pandemic on

Spani sh Nephrology Services. Nefrologia 2020;40:579-84. https://doi.org/10.1016/j.nefro.2020.08.002. 26 Krueger KM, Is on MG, Ghossein C. Practi cal guide to vaccination i n all stages of CKD, i ncluding patients treated by di alysis or ki dney transplantation. Am J Ki dney Dis 2020;75:417−25. https ://doi.org/10.1053/j.ajkd.2019.06.014 27 Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Mel amed ML, et al . Factors associated with death i n cri ti cally Ill patients wi th coronavirus disease 2019 in the US. JAMA Intern Med 2020;180(11):1436-46. 28 Li èvre A, Turpi n A, Ray-Coquard I, Le Mal icot K, Thariat J, Ahl e G, et al . Ri sk factors for Coronavirus Disease 2019 (COVID-19) s everity and mortality among s olid cancer patients and impact of the di s ease on anticancer treatment: a French nationwide cohort s tudy (GCO-002 CACOVID-19). Eur J Cancer 2020;141:62-81. 29 Pl asencia-Urizarri TM, Agui lera-Rodríguez R, Al maguer-Mederos LE. Comorbilidades y gravedad clínica de l a

COVID-19: revi sión sistemática y meta-análisis. Rev Habanera Cienc Méd 2020;19(Suppl 1):e3389. 30 Meng Y, Lu W, Guo E, Li u J, Yang B, Wu P, et al . Cancer history i s an i ndependent risk factor for mortality i n hos pitalized COVID-19 patients: a propensity s core-matched analysis. J Hematol Oncol 2020;13(1):75. 31 Park R, Lee SA, Ki m SY, de Mel o AC, Kas i A. As s ociation of acti ve oncologic treatment and risk of death in cancer patients wi th COVID-19: a systematic review and meta-analysis of patient data. Acta Oncol 2021;60(1):13-9.

32 Bri ti sh Transplantation Society. Position Statement on Vaccination against COVID-19 i n Solid Organ and Islet

Trans plant Recipients (adults, children and young people) 22nd January 2021. https://bts.org.uk/wpcontent/uploads/2021/01/22nd-January-2021-BTS-Position-Statement-on-Vaccination-in-solid-organ-and-islettrans plant-recipients-FINAL.pdf 33 Recomendaciones de vacunación en i nmunodeficiencias. https ://www.ms cbs.gob.es/en/profesionales/saludPublica/prevPromocion/vacunaciones/programasDeVacuna ci on/riesgo/docs/Inmunodeficiencias.pdf 34 Mel l or M. Ri sk of adverse coronavirus disease 2019 outcomes for people living wi th HIV. AIDS 2021:15;35. 35 Boul l e A et al . Ri sk factors for COVID-19 death i n a population cohort s tudy from the Wes tern Cape Province,

South Afri ca. Clin Infect Dis, June 2020. 36 Bhas karan K, et al . HIV i nfection and COVID-19 death: population-based cohort analysis of UK primary care data l inked national death registrations within Open SAFELY pl atform. The Lancet HIV, December 2020. 37 Actual ización del continuo de atención del VIH en Es paña, 2017-2019. https ://www.ms cbs.gob.es/ciudadanos/enfLesiones/enfTransmisibles /sida/vigilancia/ESTIMACION_DEL_CONT

INUO_DE_ATENCIoN_DEL_VIH_EN_ESPAnA_Nov2020.pdf 38 Dandachi D et al . Characteristics, comorbidities, and outcomes i n a mul ticentre regi stry of patients wi th HIV and coronavirus disease-19. Clinical Infecti ous Diseases, published online, 9 September 2020 (open access). https ://doi.org/10.1093/cid/ciaa1339 39 Cl i ft AK, Coupland CA, Keogh RH, Hemi ngway H, Hi ppisley-Cox J. COVID-19 mortality risk i n Down s yndrome: res ul ts from a cohort study of 8 mi llion adults [l etter]. Ann Intern Med 2020:M20-4986. http://dx.doi .org/10.7326/m20-4986 40 Hül s A, Cos ta AC, Di erssen M, Baksh RA, Bargagna S, Baumer NT, et al . Medi cal vulnerability of i ndividuals with down s yndrome to s evere COVID-19: data from the tri somy 21 research s ociety and the UK ISARIC4C survey.

ECl i nicalMedicine 2021:100769. 41 ECDC. Infecti on prevention and control and preparedness for COVID-19 i n healthcare s etti ngs. Disponible en: https ://www.ecdc.europa.eu/sites/default/files /documents/Infection-prevention-and-control-in-healthcares etti ngs-COVID-19_5th_update.pdf 42 Ju B, Zhang Q, Ge J, et al . Human neutralizing antibodies elicited by SARS-CoV-2 i nfection. Nature 2020; 584: 115–119. 43 Gri foni A, Wei skopf D, Ramirez SI, et al . Targets of T Cel l Res ponses to SARS-CoV-2 Coronavirus in Humans with

COVID-19 Di sease and Unexposed Individuals. Cel l 2020; 181(7): 1489-1501.e15. 44 Hal l V, Foul kes S, Charlett A, et al . Do antibody positive healthcare workers have l ower SARS-CoV-2 i nfection rates than antibody negative healthcare workers? Large mul ti-centre prospective cohort s tudy (the SIREN s tudy), Engl and: June to November 2020. medRxiv2021.01.13.21249642; doi: https ://doi.org/10.1101/2021.01.13.21249642. 45 Dan JM, Mateus J, Kato Y, et al . Immunological memory to SARS-CoV-2 assessed for up to 8 months after i nfecti on. Science 2021. Doi: 10.1126/science.abf4063. 46 Hans en CH, Mi chlmayr D, Gubbels SM, et al . As s essment of protection against rei nfection with SARS-CoV-2 among 4 mi l lion PCR-tested i ndividuals in Denmark i n 2020: a population-level observational study. Lancet. 2021 Mar 17:S0140-6736(21)00575-4. doi: 10.1016/S0140-6736(21)00575-4. Epub ahead of print. 47 Prendecki M, Cl arke C, Brown J, et al . Effect of previ ous SARS-CoV-2 i nfection on humoral and T-cell res ponses to s i ngle-dose BNT162b2 vaccine. The Lancet 2021. https://doi.org/10.1016/S0140-6736(21)00502-X 48 Mani sty C, Otter AD, Trei bel TA, et al . Anti body response to fi rst BNT162b2 dose i n previously SARS-CoV-2i nfected i ndividuals. The Lancet 2021. https ://doi.org/10.1016/S0140-6736(21)00501-8 49 Bradley T, Grundberg E, CODIEFY study team1, Sel varangan R. Anti body responses boosted i n s eropositive heal thcare workers after single dose of SARS-CoV-2 mRNA Vaccine. medRxiv preprint 2021. doi: https ://doi.org/10.1101/2021.02.03.21251078 50 Saadat S, Ri khtegaran-Tehrani Z, Logue J, Newman M, Fri eman MB, et al . Si ngle Dos e Vaccination i n Healthcare

Workers Previously Infected wi th SARS-CoV-2.medRxiv preprint 2021; doi: https ://doi.org/10.1101/2021.01.30.21250843. 51 Kamal A, Hi l a B, Karine B et al . Impact of age, ethni city, s ex and prior i nfecti on status on i mmunogenicity fol l owing a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evi dence from healthcare

workers , Israel, December 2020 to January 2021. Euro Surveill. 2021;26(6):pii=2100096. https ://doi.org/10.2807/1560-7917.ES.2021.26.6.2100096 52 Krammer F, Sri vastava K, the PARIS team, Si mon V. Anti body responses in s eropositive persons after a single dos e of SARS-CoV-2 mRNA vaccine. New Engl J Med 2021;doi 10.1056/NEJMc2101667 53 Camara C, Lozano-Ojalvo D, Lopez-Granados E, Paz-Artal E, Pi on M et al . Di fferential effects of the s econd

SARS-CoV-2 mRNA vaccine dose on T cel l i mmunity i n naive and COVID-19 recovered i ndividuals. bioRxiv 2021.03.22.436441; doi: https ://doi.org/10.1101/2021.03.22.436441 54 Samanovic M, Cornelius A, Wilson J, et al . Poor antigen-specific responses to the s econd BNT162b2 mRNA vaccine dose i n SARS-CoV-2-experienced i ndividuals. medRxiv preprint doi: https ://doi.org/10.1101/2021.02.07.21251311 55 ZOE COVID Symptom Study. Vaccine after effects more common in those who already had COVID. Di sponible en: https ://covid.joinzoe.com/post/vaccine-after-effects-more-common-in-those-who-already-had-covid 56 Stamatatos L, Czartoski J, Wan Y. Anti bodies elicited by SARS-CoV-2 i nfection and boosted by vaccination neutral ize an emergi ng variant and SARS-CoV-1. medRxiv preprint doi: https ://doi.org/10.1101/2021.02.05.21251182 57 Agenci a Es pañola de Medi camentos y Productos Sanitarios. Nota de s eguridad, 18 marzo 2021. Vacuna frente a l a COVID-19 de As traZeneca: conclusiones de l a evaluación del riesgo de tromboembolismo. Disponible en: https ://www.aemps.gob.es/informa/notasinformativas/medicamentosusohumano-3/seguridad-1/2021s eguri dad-1/vacuna-frente-a-la-covid-19-de-astrazeneca-conclusiones-de-la-evaluacion-del-riesgo-detromboembolismo/ 58 Fol egatti P, Ewer K, Parvinder, Al ey P et al . Safety and i mmunogenicity of the ChAdOx1 nCoV-19 vaccine agai nst SARS-CoV-2: a preliminary report of a phase 1/2, s ingle-blind, randomised controlled trial. The Lancet 2020; 396:467-478.